Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Holland-headquartered Clondalkin Group has acquired the printed components business of New Jersey-based Catalent Pharma Solutions.
Subscribe to our email newsletter
The 28 February 2011 deal will add four Catalent sites (in Ireland, the US and Puerto Rico) with sales of more than $100m to Clondalkin’s network of 14 pharmaceutical packaging-approved production plants in Europe and North America.
All four sites produce secondary packaging such as inserts and labels for the pharmaceutical and healthcare markets, and are expected to take Clondalkin’s sales in the pharmaceutical sector to nearly $340m.
Clondalkin will sign a long-term supply agreement with Catalent for the sites’ products and the deal is expected to make pharmaceuticals and healthcare Clondalkin’s biggest market (which will account for 28% of sales compared to 26% for food and beverage).
Clondalkin Group CEO Norbert McDermott said the deal would take the group’s pharmaceutical offering to a new level of unrivalled capabilities and possibilities in location, technology and product choices.
He also opined that bringing the Catalent business into the Clondalkin group would offer excellent business development and cross-selling opportunities in Europe.
Catalent Medication Delivery Solutions president Barry Russell said Clondalkin’s commitment to the industry aligns well with Catalent’s approach of tailoring unique product supply solutions for our customers.
The completion of the deal is subject to approval from relevant competition authorities.